Handelen Intracellular Th - ITCI CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | - | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Intra-Cellular Therapies Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Jaarlijkse Verandering* | N/A |
| Dagelijks bereik* | N/A |
| 52 wekelijks bereik | 42.01-66.56 |
| Weekgemiddelde volume (10 dagen) | 655.13K |
| Gemiddeld volume (3 maanden) | 18.55M |
| Marktkapitalisatie | 5.77B |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 95.93M |
| Omzet | 310.62M |
| EPS | -2.41 |
| Dividend (opbrengst %) | N/A |
| Beta | 1.13 |
| Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|
Intracellular Th Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Friday, June 9, 2023 | ||
| Tijd (UTC) (UTC) 15:00 | Land US
| Evenement Intra-Cellular Therapies Inc Annual Shareholders Meeting Intra-Cellular Therapies Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 23, 2023 | ||
| Tijd (UTC) (UTC) 14:00 | Land US
| Evenement Intra-Cellular Therapies Inc Annual Shareholders Meeting Intra-Cellular Therapies Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q2 2023 Intra-Cellular Therapies Inc Earnings Release Q2 2023 Intra-Cellular Therapies Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Tijd (UTC) (UTC) 12:30 | Land US
| Evenement Q3 2023 Intra-Cellular Therapies Inc Earnings Release Q3 2023 Intra-Cellular Therapies Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 250.314 | 83.803 | 22.813 | 0.06061 | 0 |
| Inkomsten | 250.314 | 83.803 | 22.813 | 0.06061 | 0 |
| Totale bedrijfskosten | 513.94 | 369.491 | 254.041 | 154.072 | 162.267 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 358.782 | 272.611 | 186.363 | 64.9476 | 30.0999 |
| Onderzoek & Ontwikkeling | 134.715 | 88.8455 | 65.7821 | 89.1248 | 132.167 |
| Bedrijfsresultaat | -263.626 | -285.688 | -231.228 | -154.012 | -162.267 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 7.376 | 1.56809 | 4.23548 | 6.29127 | 7.14096 |
| Netto inkomen voor belastingen | -256.25 | -284.12 | -226.992 | -147.721 | -155.126 |
| Netto inkomen na belastingen | -256.256 | -284.126 | -227.006 | -147.722 | -155.127 |
| Netto inkomen voor extra. Posten | -256.256 | -284.126 | -227.006 | -147.722 | -155.127 |
| Netto inkomen | -256.256 | -284.126 | -227.006 | -147.722 | -155.127 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -256.256 | -284.126 | -227.006 | -147.722 | -155.127 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -256.256 | -284.126 | -227.006 | -147.722 | -155.127 |
| Verwaterd Netto Inkomen | -256.256 | -284.126 | -227.006 | -147.722 | -155.127 |
| Verwaterd Gewogen Gemiddelde Aandelen | 94.0467 | 81.2534 | 70.3648 | 55.1862 | 54.7079 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.72477 | -3.49679 | -3.22613 | -2.6768 | -2.83556 |
| Verwaterde Genormaliseerde Winst per Aandeel | -2.72477 | -3.49679 | -3.22613 | -2.6768 | -2.83556 |
| Totale buitengewone posten | |||||
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Kosten van opbrengsten, totaal | 20.443 | 8.03459 | 1.89503 | ||
| Brutowinst | 229.871 | 75.7684 | 20.9179 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 95.306 | 87.869 | 71.87 | 55.579 | 34.996 |
| Inkomsten | 95.306 | 87.869 | 71.87 | 55.579 | 34.996 |
| Kosten van opbrengsten, totaal | 6.751 | 6.788 | 5.85 | 4.65 | 3.155 |
| Brutowinst | 88.555 | 81.081 | 66.02 | 50.929 | 31.841 |
| Totale bedrijfskosten | 143.698 | 135.281 | 127.499 | 143.502 | 107.658 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 98.923 | 94.631 | 88.375 | 100.316 | 75.46 |
| Onderzoek & Ontwikkeling | 38.024 | 33.862 | 33.274 | 38.536 | 29.043 |
| Bedrijfsresultaat | -48.392 | -47.412 | -55.629 | -87.923 | -72.662 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 4.349 | 3.386 | 2.122 | 1.32 | 0.548 |
| Netto inkomen voor belastingen | -44.043 | -44.026 | -53.507 | -86.603 | -72.114 |
| Netto inkomen na belastingen | -44.053 | -44.026 | -53.508 | -86.603 | -72.119 |
| Netto inkomen voor extra. Posten | -44.053 | -44.026 | -53.508 | -86.603 | -72.119 |
| Netto inkomen | -44.053 | -44.026 | -53.508 | -86.603 | -72.119 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -44.053 | -44.026 | -53.508 | -86.603 | -72.119 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -44.053 | -44.026 | -53.508 | -86.603 | -72.119 |
| Verwaterd Netto Inkomen | -44.053 | -44.026 | -53.508 | -86.603 | -72.119 |
| Verwaterd Gewogen Gemiddelde Aandelen | 95.1347 | 94.7593 | 94.5168 | 94.2851 | 92.6043 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.46306 | -0.46461 | -0.56612 | -0.91852 | -0.77879 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.46306 | -0.46461 | -0.56612 | -0.91852 | -0.77879 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 737.957 | 467.281 | 690.904 | 230.324 | 355.439 |
| Geldmiddelen en kortetermijnbeleggingen | 591.905 | 412.333 | 657.448 | 224.01 | 347.531 |
| Geldmiddelen & Equivalenten | 148.615 | 92.365 | 60.0459 | 107.637 | 54.9475 |
| Korte Termijn Investeringen | 443.29 | 319.968 | 597.402 | 116.373 | 292.583 |
| Totale Vorderingen, Netto | 75.189 | 20.156 | 10.7646 | ||
| Accounts Receivable - Trade, Net | 75.189 | 20.156 | 10.7646 | ||
| Prepaid Expenses | 45.193 | 25.4434 | 14.2355 | 6.31379 | 7.90813 |
| Total Assets | 754.78 | 489.922 | 717.314 | 251.186 | 357.207 |
| Property/Plant/Equipment, Total - Net | 16.737 | 22.5552 | 26.3231 | 20.5118 | 1.15977 |
| Property/Plant/Equipment, Total - Gross | 21.961 | 27.1238 | 30.3597 | 24.0203 | 4.19369 |
| Accumulated Depreciation, Total | -5.224 | -4.56867 | -4.03655 | -3.50843 | -3.03392 |
| Other Long Term Assets, Total | 0.086 | 0.08608 | 0.08608 | 0.35069 | 0.60805 |
| Total Current Liabilities | 83.236 | 53.3565 | 36.8532 | 36.224 | 36.2992 |
| Accounts Payable | 10.395 | 8.69122 | 5.50183 | 7.42502 | 13.9611 |
| Accrued Expenses | 72.841 | 44.6653 | 31.3514 | 28.799 | 22.3381 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 98.71 | 72.0314 | 60.4536 | 56.1792 | 39.4916 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 15.474 | 18.6749 | 23.6003 | 19.9552 | 3.19243 |
| Total Equity | 656.07 | 417.891 | 656.86 | 195.007 | 317.715 |
| Common Stock | 0.009 | 0.00819 | 0.00805 | 0.00555 | 0.00549 |
| Additional Paid-In Capital | 2137.74 | 1639.48 | 1593.48 | 904.972 | 880.753 |
| Retained Earnings (Accumulated Deficit) | -1477.49 | -1221.23 | -937.104 | -710.098 | -562.376 |
| Other Equity, Total | -4.19 | -0.36365 | 0.48058 | 0.12832 | -0.66776 |
| Total Liabilities & Shareholders’ Equity | 754.78 | 489.922 | 717.314 | 251.186 | 357.207 |
| Total Common Shares Outstanding | 94.8298 | 81.887 | 80.4631 | 55.5075 | 54.8953 |
| Total Inventory | 23.92 | 7.94813 | 7.05639 | ||
| Other Current Assets, Total | 1.75 | 1.4 | 1.4 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 706.094 | 737.957 | 759.756 | 789.206 | 848.342 |
| Geldmiddelen en kortetermijnbeleggingen | 538.708 | 591.905 | 628.741 | 677.829 | 771.848 |
| Geldmiddelen & Equivalenten | 75.727 | 148.615 | 135.358 | 77.235 | 129.295 |
| Korte Termijn Investeringen | 462.981 | 443.29 | 493.383 | 600.594 | 642.553 |
| Totale Vorderingen, Netto | 81.545 | 75.189 | 61.538 | 46.976 | 32.832 |
| Accounts Receivable - Trade, Net | 81.545 | 75.189 | 61.538 | 46.976 | 32.832 |
| Total Inventory | 28.341 | 23.92 | 23.597 | 25.022 | 7.893 |
| Prepaid Expenses | 55.75 | 45.193 | 44.13 | 37.979 | 34.369 |
| Other Current Assets, Total | 1.75 | 1.75 | 1.75 | 1.4 | 1.4 |
| Total Assets | 722.158 | 754.78 | 781.999 | 811.906 | 868.58 |
| Property/Plant/Equipment, Total - Net | 15.978 | 16.737 | 22.157 | 22.614 | 20.152 |
| Property/Plant/Equipment, Total - Gross | 21.961 | ||||
| Accumulated Depreciation, Total | -5.224 | ||||
| Other Long Term Assets, Total | 0.086 | 0.086 | 0.086 | 0.086 | 0.086 |
| Total Current Liabilities | 79.587 | 83.236 | 77.41 | 70.634 | 59.074 |
| Accounts Payable | 8.441 | 10.395 | 14.219 | 10.749 | 11.649 |
| Accrued Expenses | 71.146 | 72.841 | 63.191 | 59.885 | 47.425 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 94.548 | 98.71 | 96.577 | 89.709 | 75.83 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 14.961 | 15.474 | 19.167 | 19.075 | 16.756 |
| Total Equity | 627.61 | 656.07 | 685.422 | 722.197 | 792.75 |
| Common Stock | 0.01 | 0.009 | 0.009 | 0.009 | 0.009 |
| Additional Paid-In Capital | 2151.84 | 2137.74 | 2124.37 | 2106.94 | 2089.42 |
| Retained Earnings (Accumulated Deficit) | -1521.54 | -1477.49 | -1433.46 | -1379.95 | -1293.35 |
| Other Equity, Total | -2.698 | -4.19 | -5.496 | -4.802 | -3.328 |
| Total Liabilities & Shareholders’ Equity | 722.158 | 754.78 | 781.999 | 811.906 | 868.58 |
| Total Common Shares Outstanding | 95.68 | 94.8298 | 94.7017 | 94.3672 | 94.0204 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -256.256 | -284.126 | -227.006 | -147.722 | -155.127 |
| Geldmiddelen uit Operationele Activiteiten | -270.186 | -259.543 | -230.073 | -127.983 | -118.169 |
| Geldmiddelen uit Operationele Activiteiten | 0.656 | 0.53336 | 0.52812 | 0.47712 | 0.36867 |
| Niet-Geldelijke Posten | 43.55 | 30.4017 | 23.681 | 19.8513 | 16.6454 |
| Cash Taxes Paid | 0.006 | 0.00563 | 0.0016 | 0.0016 | 0.0016 |
| Contant Betaalde Rente | 0 | 0 | |||
| Veranderingen in het Operationeel Kapitaal | -58.136 | -6.35291 | -27.541 | -0.85409 | 19.415 |
| Geldmiddelen uit Investeringsactiviteiten | -128.373 | 280.344 | -480.295 | 177.437 | 134.641 |
| Kapitaaluitgaven | -0.778 | -0.32574 | -0.26672 | -0.7004 | -0.39127 |
| Overige Cash Flow investeringsposten, Totaal | -127.595 | 280.669 | -480.028 | 178.137 | 135.033 |
| Geldmiddelen uit Financieringsactiviteiten | 455.159 | 11.5189 | 664.177 | 3.2356 | 0.68519 |
| Financiering van Cash Flow Posten | |||||
| Uitgifte (Aflossing) van aandelen, netto | 455.159 | 11.5189 | 664.177 | 3.2356 | 0.68519 |
| Uitgifte (Aflossing) van Schulden, Netto | 0 | ||||
| Nettowijziging in Geldmiddelen | 56.6 | 32.3191 | -46.1909 | 52.6894 | 17.1574 |
| Deferred Taxes | 0 | 0 | 0.26461 | 0.26461 | 0.52922 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -44.053 | -256.256 | -212.23 | -158.722 | -72.119 |
| Cash From Operating Activities | -60.066 | -270.186 | -230.993 | -177.642 | -82.849 |
| Cash From Operating Activities | 0.134 | 0.656 | 0.513 | 0.343 | 0.171 |
| Deferred Taxes | 0 | ||||
| Non-Cash Items | 8.724 | 43.55 | 31.205 | 19.202 | 4.05 |
| Changes in Working Capital | -24.871 | -58.136 | -50.481 | -38.465 | -14.951 |
| Cash From Investing Activities | -16.462 | -128.373 | -178.636 | -284.806 | -322.035 |
| Capital Expenditures | 0 | -0.778 | -0.806 | -0.689 | -0.566 |
| Other Investing Cash Flow Items, Total | -16.462 | -127.595 | -177.83 | -284.117 | -321.469 |
| Cash From Financing Activities | 3.64 | 455.159 | 452.972 | 447.318 | 441.814 |
| Issuance (Retirement) of Stock, Net | 3.64 | 455.159 | 452.972 | 447.318 | 441.814 |
| Net Change in Cash | -72.888 | 56.6 | 43.343 | -15.13 | 36.93 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Fidelity Management & Research Company LLC | Investment Advisor | 12.4403 | 11933441 | -90520 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.7847 | 8426729 | 123908 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.4319 | 6169834 | -132203 | 2023-03-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 5.2382 | 5024783 | -384902 | 2023-03-31 | LOW |
| Alafi Capital Company, LLC | Venture Capital | 4.9453 | 4743770 | 0 | 2023-04-01 | LOW |
| Wasatch Global Investors Inc | Investment Advisor/Hedge Fund | 4.6698 | 4479576 | -260569 | 2023-03-31 | LOW |
| Bellevue Asset Management AG | Investment Advisor | 3.4068 | 3268000 | -74236 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.1123 | 2026228 | 31225 | 2023-03-31 | LOW |
| AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 2.0881 | 2003050 | -10697 | 2023-03-31 | LOW |
| Invesco Advisers, Inc. | Investment Advisor | 1.8688 | 1792640 | 45417 | 2023-03-31 | LOW |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 1.8571 | 1781474 | -721 | 2023-03-31 | LOW |
| GW&K Investment Management, LLC | Investment Advisor | 1.8275 | 1753067 | 302685 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8233 | 1749018 | 77581 | 2023-03-31 | LOW |
| Deep Track Capital LP | Hedge Fund | 1.7722 | 1700000 | 1700000 | 2023-03-31 | MED |
| Suvretta Capital Management, LLC | Hedge Fund | 1.2499 | 1198971 | 162023 | 2023-03-31 | MED |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.2318 | 1181604 | 182612 | 2023-03-31 | LOW |
| JP Morgan Asset Management | Investment Advisor | 1.2226 | 1172775 | 248018 | 2023-03-31 | LOW |
| Mates (Sharon) | Individual Investor | 1.1992 | 1150309 | 38925 | 2023-04-01 | LOW |
| Holocene Advisors, LP | Hedge Fund | 1.1637 | 1116264 | -614829 | 2023-03-31 | HIGH |
| ClearBridge Investments, LLC | Investment Advisor/Hedge Fund | 1.0945 | 1049875 | 390493 | 2023-03-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group530K+
Handelaren
87K+
Actieve klanten per maand
$46M+
Maandelijks beleggingsvolume
$31M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Intracellular Th Company profile
Over Intracellular Th
Intra-Cellular Therapies, Inc. is een biofarmaceutisch bedrijf. Het bedrijf richt zich op de ontdekking, klinische ontwikkeling en commercialisering van kleine moleculegeneesmiddelen die tegemoetkomen aan onderverdiende medische behoeften, voornamelijk in neuropsychiatrische en neurologische aandoeningen, door zich te richten op intracellulaire signaalmechanismen binnen het centrale zenuwstelsel (CZS). De Vennootschap levert CAPLYTA (lumateperone) voor de behandeling van schizofrenie bij volwassenen. CAPLYTA is een geneesmiddel op voorschrift dat wordt gebruikt voor de behandeling van depressieve episoden bij volwassenen met bipolair I of II, dat alleen of samen met lithium of valproaat kan worden ingenomen. De pijplijn van de Vennootschap is gericht op drie platformen: lumateperone en vervolgverbindingen, een platform voor fosfodiesterase 1 (PDE1)-inhibitoren en een ontdekkingsplatform dat ITI-333 bevat, een nieuwe verbinding met hoge affiniteit voor serotonine 5-HT2A-, dopamine D1- en mu opioïde (MOP)-receptoren. De dochterondernemingen van de onderneming zijn ITI, Inc. (ITI) en ITI Limited.
| Industry: | Bio Therapeutic Drugs |
430 East 29th Street
NEW YORK
NEW YORK 10016
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 530.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen